Pretax income is the income that a company earns before paying income taxes. Nuvation Bio's pretax income for the
three
months ended in Dec. 2024 was $-49.45 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-567.94 Mil.
Nuvation Bio's pretax margin was -865.79%.
During the past 5 years, Nuvation Bio's highest Pretax Margin was -7213.76%. The lowest was -7213.76%. And the median was -7213.76%.
Nuvation Bio Pre-Tax Income Historical Data
The historical data trend for Nuvation Bio's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuvation Bio's Pre-Tax Income
For the Biotechnology subindustry, Nuvation Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-567.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NYSE:NUVB) Pre-Tax Income Explanation
Nuvation Bio's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 5 years, Nuvation Bio's highest Pretax Margin was -7213.76%. The lowest was -7213.76%. And the median was -7213.76%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 